应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
RVMD Revolution Medicines, Inc.
盘后交易 06-08 17:42:18 EDT
148.49
-0.74
-0.50%
盘后
149.40
+0.91
+0.61%
17:36 EDT
最高
152.10
最低
147.41
成交量
273.07万
今开
150.10
昨收
149.23
日振幅
3.14%
总市值
315.68亿
流通市值
280.65亿
总股本
2.13亿
成交额
4.07亿
换手率
1.44%
流通股本
1.89亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜Revolution Medicines盘中下跌5.13%，ASCO大会胰腺癌数据利好兑现后股价高位回落
行情直击 · 06-02
异动解读｜Revolution Medicines盘中下跌5.13%，ASCO大会胰腺癌数据利好兑现后股价高位回落
异动解读｜Revolution Medicines盘中上涨5.11%，ASCO大会胰腺癌III期数据大超预期持续提振股价
行情直击 · 06-02
异动解读｜Revolution Medicines盘中上涨5.11%，ASCO大会胰腺癌III期数据大超预期持续提振股价
异动解读｜Revolution Medicines盘前上涨15.38%，ASCO大会胰腺癌III期数据大超预期引爆市场
行情直击 · 06-01
异动解读｜Revolution Medicines盘前上涨15.38%，ASCO大会胰腺癌III期数据大超预期引爆市场
异动解读｜Revolution Medicines夜盘上涨7.95%，ASCO大会RAS抑制剂胰腺癌数据引爆市场热情
行情直击 · 06-01
异动解读｜Revolution Medicines夜盘上涨7.95%，ASCO大会RAS抑制剂胰腺癌数据引爆市场热情
谷歌母公司Alphabet披露持仓变动：增持PayPay与CME集团，清仓德康医疗
投资观察 · 05-08
谷歌母公司Alphabet披露持仓变动：增持PayPay与CME集团，清仓德康医疗
Revolution Medicines获FDA"安全进行"函，启动Daraxonrasib治疗胰腺癌的扩大用药方案
美股速递 · 05-01
Revolution Medicines获FDA"安全进行"函，启动Daraxonrasib治疗胰腺癌的扩大用药方案
异动解读 | Revolution Medicines盘中大涨9.91%，受积极临床数据及竞争对手安全事件提振
异动解读 · 04-28
异动解读 | Revolution Medicines盘中大涨9.91%，受积极临床数据及竞争对手安全事件提振
Revolution Medicines完成同步增发募资约22亿美元 承销商超额配售权全额行使
美股速递 · 04-18
Revolution Medicines完成同步增发募资约22亿美元 承销商超额配售权全额行使
异动解读 | 宣布20亿美元增发计划，Revolution Medicines盘中大涨5.18%
异动解读 · 04-16
异动解读 | 宣布20亿美元增发计划，Revolution Medicines盘中大涨5.18%
Revolution Medicines(RVMD)宣布定价20亿美元增发：含普通股与可转换优先票据
金吾财讯 · 04-15
Revolution Medicines(RVMD)宣布定价20亿美元增发：含普通股与可转换优先票据
Revolution Medicines提交SEC文件：计划发行1060万股普通股及5亿美元可转换优先票据
美股速递 · 04-15
Revolution Medicines提交SEC文件：计划发行1060万股普通股及5亿美元可转换优先票据
Revolution Medicines, Inc. 完成总额20亿美元普通股及可转换优先票据同步增发定价
美股速递 · 04-15
Revolution Medicines, Inc. 完成总额20亿美元普通股及可转换优先票据同步增发定价
Revolution Medicines胰腺癌药物取得成功
环球市场播报 · 04-14
Revolution Medicines胰腺癌药物取得成功
Revolution Medicines盘后股价下跌1.6% 宣布拟公开发行普通股及可转换优先票据
美股速递 · 04-14
Revolution Medicines盘后股价下跌1.6% 宣布拟公开发行普通股及可转换优先票据
Revolution Medicines Inc拟发行7.5亿美元普通股及2.5亿美元2033年到期可转换优先票据
美股速递 · 04-14
Revolution Medicines Inc拟发行7.5亿美元普通股及2.5亿美元2033年到期可转换优先票据
抗癌新药晚期研究显成效，Revolution Medicines盘前股价飙升33.5%
美股速递 · 04-13
抗癌新药晚期研究显成效，Revolution Medicines盘前股价飙升33.5%
Daraxonrasib在转移性胰腺癌关键3期Rasolute 302临床试验中展现前所未有的总生存期获益
美股速递 · 04-13
Daraxonrasib在转移性胰腺癌关键3期Rasolute 302临床试验中展现前所未有的总生存期获益
Revolution Medicines：Daraxonrasib在针对转移性胰腺癌患者的3期Rasolute 302试验中显示总体生存获益
美股速递 · 04-13
Revolution Medicines：Daraxonrasib在针对转移性胰腺癌患者的3期Rasolute 302试验中显示总体生存获益
Revolution Medicines：Daraxonrasib在胰腺癌患者中总体耐受性良好，安全性可控且无新发风险信号
美股速递 · 04-13
Revolution Medicines：Daraxonrasib在胰腺癌患者中总体耐受性良好，安全性可控且无新发风险信号
Revolution Medicines启动Rasolute 303三期临床试验，评估Daraxonrasib作为转移性胰腺癌一线疗法
美股速递 · 04-02
Revolution Medicines启动Rasolute 303三期临床试验，评估Daraxonrasib作为转移性胰腺癌一线疗法
加载更多
公司概况
公司名称：
Revolution Medicines, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。
发行价格：
--
{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":148.49,"timestamp":1780948800000,"preClose":149.23,"halted":0,"volume":2730702,"hourTrading":{"tag":"盘后","latestPrice":149.4,"preClose":148.49,"latestTime":"17:36 EDT","volume":638469,"amount":94812569.88372,"timestamp":1780954570960,"change":0.91,"changeRate":0.006128,"amplitude":0.023134},"delay":0,"changeRate":-0.004958788447363001,"floatShares":189000000,"shares":212592561,"eps":-7.121384,"marketStatus":"盘后交易","change":-0.74,"latestTime":"06-08 17:42:18 EDT","open":150.1,"high":152.1,"low":147.41,"amount":406965393.84150004,"amplitude":0.031428,"askPrice":151.39,"askSize":13,"bidPrice":148,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-7.121384,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780963200000},"marketStatusCode":4,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":149.23,"preHourTrading":{"tag":"盘前","latestPrice":150.94,"preClose":149.23,"latestTime":"09:29 EDT","volume":19741,"amount":2992000.64257,"timestamp":1780925399999,"change":1.71,"changeRate":0.011459,"amplitude":0.031763},"postHourTrading":{"tag":"盘后","latestPrice":149.4,"preClose":148.49,"latestTime":"17:36 EDT","volume":638469,"amount":94812569.88372,"timestamp":1780954570960,"change":0.91,"changeRate":0.006128,"amplitude":0.023134},"volumeRatio":0.792,"impliedVol":0.5987,"impliedVolPercentile":0.6454},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"1113096257","title":"异动解读｜Revolution Medicines盘中下跌5.13%，ASCO大会胰腺癌数据利好兑现后股价高位回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1113096257","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113096257?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:39","pubTimestamp":1780411180,"startTime":"0","endTime":"0","summary":"6月2日，Revolution Medicines盘中下跌5.13%，报153.18美元/股，成交额1.91亿美元。消息面上，此前ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，该数据同步发表于《新英格兰医学杂志》，被视为RAS靶向治疗里程碑突破。受此利好驱动，公司股价此前夜盘及盘前累计涨幅已超15%，奥本海默同步上调目标价至195美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105705147","title":"异动解读｜Revolution Medicines盘中上涨5.11%，ASCO大会胰腺癌III期数据大超预期持续提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1105705147","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105705147?lang=zh_cn&edition=full","pubTime":"2026-06-02 02:52","pubTimestamp":1780339963,"startTime":"0","endTime":"0","summary":"6月2日，Revolution Medicines盘中上涨5.11%，报165.445美元/股，成交额7.53亿美元。消息面上，ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，入组500名既往接受过治疗的转移性胰腺导管腺癌患者。结果显示，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，数据同步发表于《新英格兰医学杂志》。该数据首次将二线胰腺癌中位OS拉长至1年以上，被视为RAS靶向治疗的里程碑突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139903431","title":"异动解读｜Revolution Medicines盘前上涨15.38%，ASCO大会胰腺癌III期数据大超预期引爆市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1139903431","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139903431?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:02","pubTimestamp":1780300930,"startTime":"0","endTime":"0","summary":"6月1日，Revolution Medicines盘前上涨15.38%，报181.33美元/股，成交额43.73万美元。消息面上，ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，该研究入组500名既往接受过治疗的转移性胰腺导管腺癌患者。结果显示，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，数据同步发表于《新英格兰医学杂志》。公司同步推进daraxonrasib一线治疗及联合用药试验，商业化前景持续扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127581925","title":"异动解读｜Revolution Medicines夜盘上涨7.95%，ASCO大会RAS抑制剂胰腺癌数据引爆市场热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1127581925","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127581925?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:01","pubTimestamp":1780272081,"startTime":"0","endTime":"0","summary":"6月1日，Revolution Medicines夜盘上涨7.95%，报170.0美元/股，成交额1.31万美元。消息面上，ASCO大会即将集中展示公司核心品种daraxonrasib的III期RASolute 302研究数据。胰腺癌长期被视为最难攻克的癌种之一，5年相对生存率仅约13%，该数据被视为RAS靶向治疗在胰腺癌领域的里程碑突破，ASCO正式报告在即，市场提前反映乐观预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139383641","title":"谷歌母公司Alphabet披露持仓变动：增持PayPay与CME集团，清仓德康医疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1139383641","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139383641?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:36","pubTimestamp":1778236606,"startTime":"0","endTime":"0","summary":"根据最新提交的监管文件显示，Alphabet公司在截至2026年3月31日的季度内对其投资组合进行了显著调整。这家科技巨头披露持有PayPay公司310万份赞助存托凭证，同时增持Planet Labs Pbc公司10.4%的A类股份，使其总持股量达到3520万股。在金融领域，Alphabet报告持有芝加哥商品交易所约350万股股份。此外，Alphabet还披露持有Ethos Technologies公司380万份A类股份，同时将其在Revolution Medicines公司的持股比例削减1.6%，目前持有330万股。这些持仓变动均以2025年12月31日为基准进行对比。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e66574f546433baec9380ca78bea95c0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989764664.SGD","LU0170899867.USD","LU1400636491.USD","LU2433249047.HKD","LU1935042488.USD","LU1066051811.HKD","LU2430703095.HKD","LU0642271901.SGD","LU2133065610.SGD","LU0070217475.USD","LU0154236417.USD","LU1551013342.USD","LU0823421416.USD","BK4082","LU0149725797.USD","LU0057025933.USD","LU2210149790.SGD","SG9999014880.SGD","LU2023250843.SGD","LU2417539215.USD","BK4598","LU0323591593.USD","LU0784383803.USD","IE0000B7K699.USD","LU2506952097.USD","LU0689472784.USD","LU0354030438.USD","LU1935042215.USD","IE000SO60NU8.SGD","LU2023250330.USD","BK4550","LU0477156797.USD","LU0208291251.USD","LU0203347892.USD","LU0345769128.USD","LU0124676726.USD","LU0310799852.SGD","LU2462591277.SGD","LU0320765489.SGD","LU0256863902.USD","LU1145028129.USD","LU2244417387.USD","LU2471134879.HKD","LU1935043023.USD","LU0289739343.SGD","GOOY","LU0080751232.USD","LU0174119429.USD","BK4588","LU2168564065.EUR","LU1894683264.USD","LU2125909593.SGD","LU1153585028.USD","SGXZ99366536.SGD","CME","LU0912757837.SGD","LU0256863811.USD","LU0211328371.USD","LU2456880835.USD","LU1066051225.USD","LU2750360997.AUD","LU0444971666.USD","LU1280957306.USD","LU0143551892.USD","LU2237438978.USD","LU2505996681.GBP","LU1043141396.HKD","LU0320765059.SGD","LU0950375773.USD","LU1989764748.USD","LU2362541513.USD","LU1400636574.HKD","LU0976567544.SGD","BK4077","LU1481011911.USD","LU1868836591.USD","BK4139","LU1116320737.USD","LU2362541273.HKD","LU0742534661.SGD","LU0689626769.HKD","LU2275660780.HKD","LU1043141123.HKD","LU2404859667.USD","LU0127658192.USD","LU0158827948.USD","LU2756315664.SGD","LU1599440770.SGD","LU0234570918.USD","IE000MB6IJN5.SGD","IE00BLSP4239.USD","LU1629891620.HKD","LU1232071149.USD","LU1084165304.USD","LU2360032135.SGD","LU0048584097.USD","LU1778281490.HKD","IE00B42XCP33.USD","LU2106854487.HKD","LU1119994496.HKD","LU1923622614.USD","BK4227","LU2087625088.SGD","LU1670756490.USD","LU0345769631.USD","LU2471134523.USD","LU0265550946.USD","LU0107464264.USD","LU0312595415.SGD","LU1244550221.USD","GOOW","IE00B19Z9505.USD","LU0823417653.USD","LU0553294199.USD","BK4576","LU2250418816.HKD","LU2242650005.HKD","LU1868836757.USD","LU0545562505.USD","LU2087621335.USD","PL","LU2750360641.GBP","LU0251142724.SGD","LU0787776722.HKD","LU1803068623.USD","LU2065171402.SGD","HK0000532082.HKD","LU2054465674.USD","BK4538","IE00BMPRXN33.USD","SG9999014914.USD","LU0444973449.USD","SG9999018857.SGD","LU1670628061.USD","LU2098885051.SGD","BK4112","SG9999000418.SGD","IE00B19Z3B42.SGD","LU0096362180.USD","LU0511384066.AUD","LU0130102774.USD","LU2430703251.USD","BK4551","IE00BWXC8680.SGD","BK4121","LU0130517989.USD","LU2462157665.USD","LU0234572021.USD","LU1064131342.USD","LU0957791311.USD","LU2236285917.USD","LU1868836914.USD","SGXZ31699556.SGD","BK4581","LU0211331839.USD","IE00BHPRN162.USD","BK4585","SGXZ51526630.SGD","LU1951200564.SGD","BK4007","LU0048573561.USD","LU1791710582.SGD","LU0342679015.USD","LU0211327993.USD","BK4574","LU1429558221.USD","LU2125154778.USD","LU0757428866.USD","IE00BK4W5M84.HKD","LU1839511570.USD","LU0496365809.HKD","LU0006306889.USD","LU0731783394.SGD","LU1244550577.SGD","LU0128525929.USD","LU0648000940.SGD","IE00B1XK9C88.USD","IE00BJTD4V19.USD","LU2211815571.USD","LU0029864427.USD","LU1267930730.SGD","LU1261432733.SGD","LU2168564149.EUR","LU0106261372.USD","LU0494093205.USD","LU0061475181.USD","LU0949170426.SGD","LU2430703178.SGD","LU1066053197.SGD","IE00B7SZLL34.SGD","LU0310800965.SGD","SG9999015986.USD","IE00B3PB1722.GBP","LU0266013472.USD","LU1633808545.USD","LU2023250504.SGD","IE000WAW04H5.SGD","LU0426417589.USD","IE00B19Z8W00.USD","LU1989772923.USD","PLU","LU0417517546.SGD","LU0096364046.USD","LU1989772840.SGD","LU2063271972.USD","LU0345774631.USD","LU0198837287.USD","LU1988902786.USD","IE0004091025.USD","LU1642822529.SGD","LU1852331112.SGD","LU1003077747.HKD","LU0211326839.USD","LU2362540622.SGD","LU0077335932.USD","LU2097829019.USD","LU1032955483.USD","BK4504","LU1121112475.USD","LU2491049909.HKD","LU2168563687.JPY","LU1430594728.SGD","LU1548497426.USD","LU0661504455.SGD","LU0211326755.USD","IE00BBT3K403.USD","LU2746668461.USD","LU1066051498.USD","LU0061474960.USD","LU2097344357.USD","LU1435385759.SGD","LU1868837136.USD","BK4173","FULC","LU1551013425.SGD","LU1201861165.SGD","LU1674673691.USD","BK4533","LU2097344431.USD","IE00BQXX3F31.USD","LU1506573853.SGD","LU0056508442.USD","IE00BFMHRM44.USD","LU0820561818.USD","LU0823434740.USD","LU1221951046.USD","LU1585245621.USD","SGXZ81514606.USD","LU0215105999.USD","LU2506951958.HKD","LU0314106906.USD","LU2077746001.SGD","LU2403377893.USD","IE000M9KFDE8.USD","LU1267930227.SGD","LU1509826696.USD","BK4592","LU0157215616.USD","LU1235294995.USD","DXCM","LU0823417737.USD","LU0792757196.USD","BK4534","LU0708995401.HKD","IE0034235188.USD","LU0772969993.USD","LU0138981039.USD","LU1732800096.USD","LU1868837300.USD","LU2420271590.USD","IE0001KFT4U8.USD","IE00BKDWB100.SGD","LU1917777945.USD","LU1914381329.SGD","BK4612","LU0345770993.USD","LU0353189763.USD","LU1059921491.USD","LU0943347566.SGD","LU0348723411.USD","LU1815336091.USD","LU1880398554.USD","LU2089284900.SGD","LU0097036916.USD","IE000F7OJYX1.SGD","LU1804176565.USD","LU1791710400.SGD","LU2023251221.USD","LU2264538146.SGD","IE00BVYPNW00.USD","LU0868494708.USD","LU0011850046.USD","IE00BMPRXQ63.HKD","LU0289960550.SGD","LU2247934214.USD","HK0000819398.USD","LU2491050154.USD","BK4561","LU2462591350.SGD","BK4563","LU2092937148.SGD","LU0823434583.USD","LU0012050646.USD","IE00BDRTCR15.USD","LU0345768740.USD","LU0820561909.HKD","LU1303367103.USD","SG9999015978.USD","IE00B3T34201.USD","LU0276348264.USD","BK4527","LU0128525689.USD","LU1645745479.HKD","LU1496350171.SGD","BK4503","LU0345774391.USD","LU1823568750.SGD","BK4123","LU1267930573.SGD","LU0820562030.AUD","PAYP","IE00BKPKM429.USD","IE00BYXW3230.USD","LU0310800379.SGD","LU1316542783.SGD","LU1670627923.USD","LU0353189680.USD","GGLL","IE00BQXX3C00.GBP","LU1951198990.SGD","LU1366192091.USD","LU0964807845.USD","LU1196500208.SGD","IE00BSNM7G36.USD","LU1267930490.SGD","IE00BDGV0183.EUR","LU0868494617.USD","LU1935043536.SGD","LU1815336760.USD","LU2065169927.USD","LU0314104364.USD","GB00B4QBRK32.GBP","LU1116320901.HKD","LU0528227936.USD","LU0784385170.HKD","LU2954938101.SGD","BK4532","BK4566","IE00BK4W5L77.USD","LU0070302665.USD","SG9999015952.SGD","GOU","BK4514","LU0109391861.USD","LU0980610538.SGD","LU0690374961.EUR","LU0130103400.USD","IE00BDCRKT87.USD","BK4602","IE00B1BXHZ80.USD","LU0731783048.USD","LU0557290698.USD","LU0742537680.HKD","LU0784385840.USD","LU0354030511.USD","LU0476273544.USD","LU0823421333.USD","LU0949170772.SGD","LU2125909247.SGD","LU2089283258.USD","LU0708994859.HKD","LU0265550359.USD","LU0889566641.SGD","LU2471134952.CNY","IE00BJLML261.HKD","LU2210150020.SGD","IE00B19Z8X17.USD","LU0690374615.EUR","LU1201861249.SGD","LU1974910355.USD","LU0640476718.USD","LU0203345920.USD","LU2357305700.SGD","IE0002270589.USD","LU1571399168.USD","LU0672654240.SGD","LU1267930813.SGD","LU1496350502.SGD","IE00BN8TJ469.HKD","SG9999017495.SGD","IE000BZT7R73.USD","LU0302445910.USD","IE0034235295.USD","WGS","LU2404859741.USD","LU2860962120.EUR","LU0784384876.USD","LU1228905037.USD","IE00BJTD4N35.SGD","IE00BLSP4452.SGD","LU1244550494.USD","LU0267386448.USD","LU0957808578.USD","GOOP","LU0683600562.USD","IE00B19Z3581.USD","LU0316494557.USD","SG9999018865.SGD","BK4548","BK4579","RVMD","LU0210533765.USD","LU1935042991.SGD","LU2360106780.USD","LU2506951875.HKD","SG9999014906.USD","LU1720051108.HKD","GOOX","GOOGL","HK0000304797.USD","LU0426412945.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU0175139822.USD","LU1481011671.HKD","LU0130518102.USD","LU0225283273.USD","IE00BMPRXR70.SGD","BK4543","LU2592432038.USD","LU0094547139.USD","LU0738911758.USD","SG9999014898.SGD","LU0187121727.USD","LU0994945656.USD","LU2092627202.USD","LU2602419157.SGD","LU0985320562.USD","LU0545039389.USD","LU0106261612.USD","LU0795875169.SGD","LU2168564495.EUR","LU1923623000.USD","LU0251132253.USD","LU2505996509.AUD","LU2491050071.SGD","LU1202635105.USD","LU0477156953.USD","LU2326559502.SGD","LU0648001328.SGD","LU1674673428.USD","LU2242649171.HKD","IE00BKVL7J92.USD","BK4196","LU1221951129.SGD","LU0289961442.SGD","IE00BQXX3D17.EUR","IE00BVYPNV92.GBP","LU1323610961.USD","LU1815333072.USD","LU0069063385.USD","LU2095319765.USD","LU1880398471.USD","LU2381873111.SGD","LU2999663052.SGD","LU0061474705.USD","IE0034235303.USD","LU0795875086.SGD","LU1699723380.USD","LU0251131958.USD","LU0052756011.USD","LU1366333091.USD","BK4573","LU0345770308.USD","LU2065171311.SGD","RGEN","LU2746668974.SGD","LU0158827781.USD","LU2168564222.USD","LU2028103732.USD","GB00B4LPDJ14.GBP","LU2471134796.USD","LU2265009873.SGD","IE00BGHQF631.EUR","LU1718418525.SGD","LU0942090050.USD","IE0004086264.USD","LU2191332357.HKD","LU1732799900.SGD","LU1720051017.SGD","LU1228905540.USD","LU2111349929.HKD","LU0472753341.HKD","LU2065170008.USD","LU2506952170.USD","LU2213496289.HKD","LU1400636657.SGD","LU2125154935.USD","LU1046421795.USD","GGLS","HK0000304805.HKD","LU2271345857.HKD","LU0345768153.USD","SG9999015945.SGD","LU2756315318.SGD","LU1894683348.USD","LIFE","LU1301847155.USD","LU0466842654.USD","LU2347655156.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164920364","title":"Revolution Medicines获FDA\"安全进行\"函，启动Daraxonrasib治疗胰腺癌的扩大用药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1164920364","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164920364?lang=zh_cn&edition=full","pubTime":"2026-05-01 23:51","pubTimestamp":1777650678,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已向Revolution Medicines, Inc.发出\"安全进行\"函，批准启动其候选药物Daraxonrasib针对胰腺癌患者的扩大用药治疗方案。\n该函件的获得意味着Revolution Medicines可以开始为符合条件的胰腺癌患者提供这种实验性治疗药物。扩大用药方案旨在让尚未参与临床试验的患者能够获得有前景的研究性疗法。\nDaraxonrasib是Revolution Medicines研发的一种靶向治疗药物，此次获批的扩大用药方案将为胰腺癌患者提供新的治疗选择。这一进展标志着该药物在临床开发道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179777848","title":"异动解读 | Revolution Medicines盘中大涨9.91%，受积极临床数据及竞争对手安全事件提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1179777848","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179777848?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:35","pubTimestamp":1777383335,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. 今日盘中股价大涨9.91%，引起了市场的广泛关注。消息面上，公司此前在AACR会议上发布的胰腺癌新药daraxonrasib积极临床数据构成了基本面的重要支撑。尽管Erasca的药物在试验中显示出较高的肿瘤反应率，但此次安全事件引发了市场对竞争对手的担忧。有分析指出，在同一试验中，Erasca药物的疗效数据优于Revolution Medicines的竞争药物daraxonrasib，但RBC资本市场认为，Revolution Medicines在RAS治疗领域仍保持着明显的领先地位。市场情绪的对比可能进一步推动了资金流向被视为更安全的标的Revolution Medicines。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124949914","title":"Revolution Medicines完成同步增发募资约22亿美元 承销商超额配售权全额行使","url":"https://stock-news.laohu8.com/highlight/detail?id=1124949914","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124949914?lang=zh_cn&edition=full","pubTime":"2026-04-18 04:03","pubTimestamp":1776456191,"startTime":"0","endTime":"0","summary":"生物制药公司Revolution Medicines, Inc. (RVMD)宣布已完成同步扩大规模的公开发行，总募资金额约达22亿美元。此次发行包含承销商全额行使超额配售权购入的额外股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186662574","title":"异动解读 | 宣布20亿美元增发计划，Revolution Medicines盘中大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186662574","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186662574?lang=zh_cn&edition=full","pubTime":"2026-04-16 03:01","pubTimestamp":1776279666,"startTime":"0","endTime":"0","summary":"生物技术公司Revolution Medicines, Inc. 今日盘中股价大幅上涨5.18%，引起了市场的广泛关注。消息面上，该公司于今日宣布对其同步进行的普通股和可转换优先票据公开发行进行定价，将融资总额大幅上调至约20亿美元。同时，公司还将发行总额5亿美元、2033年到期、年利率0.50%的可转换优先票据，该规模也由原计划的2.5亿美元实现翻倍。此外，市场亦关注该公司与Tango Therapeutics在抗癌药物vopimetostat上的合作进展。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627289764","title":"Revolution Medicines(RVMD)宣布定价20亿美元增发：含普通股与可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2627289764","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627289764?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:36","pubTimestamp":1776253004,"startTime":"0","endTime":"0","summary":"本次普通股和票据的发行预计将分别于2026年4月16日和4月17日完成交割，两项发行的完成互不作为前提条件。可转换优先票据方面：公司同步发行总额为5亿美元、2033年到期、年利率为0.50%的可转换优先票据。其初始转换价格约为每股198.80美元，较本次普通股发行价溢价约40.0%。本次两项发行规模均大幅上调，预计募资总额高达约20亿美元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NDc2NDdkNmE3OTQ1ODAzNzE4MGUxMjI3MTI4NzA1NDk3.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDc2NDdkNmE3OTQ1ODAzNzE4MGUxMjI3MTI4NzA1NDk3.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299242","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142978648","title":"Revolution Medicines提交SEC文件：计划发行1060万股普通股及5亿美元可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1142978648","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142978648?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:14","pubTimestamp":1776248067,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件显示，Revolution Medicines, Inc.正式启动融资计划。该公司拟公开发行1060万股普通股，同时发行总规模达5亿美元的可转换优先票据。\n此次融资方案将结合股权与债权工具，凸显企业多元化资本运作策略。可转换票据的发行将为投资者提供债转股选择权，进一步拓宽公司资本补充渠道。市场分析认为，此举或为后续研发管线推进及业务扩张储备资金动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108861803","title":"Revolution Medicines, Inc. 完成总额20亿美元普通股及可转换优先票据同步增发定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1108861803","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108861803?lang=zh_cn&edition=full","pubTime":"2026-04-15 12:42","pubTimestamp":1776228134,"startTime":"0","endTime":"0","summary":"生物制药公司Revolution Medicines, Inc. 已成功为其同步进行的增发交易完成定价，此次发行包括普通股及可转换优先票据，募集资金总额高达20亿美元。该交易规模较最初计划有所扩大，显示出市场对其融资方案的强劲需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627441319","title":"Revolution Medicines胰腺癌药物取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441319","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627441319?lang=zh_cn&edition=full","pubTime":"2026-04-14 21:09","pubTimestamp":1776172140,"startTime":"0","endTime":"0","summary":"Revolution Medicines表示，daraxonrasib在既往接受过治疗的胰腺癌中达到了3期临床试验终点，将中位总生存期延长一倍至13.2个月（化疗组为6.7个月），并计划寻求FDA审查。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-14/doc-inhunpmv9018109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118425869","title":"Revolution Medicines盘后股价下跌1.6% 宣布拟公开发行普通股及可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1118425869","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118425869?lang=zh_cn&edition=full","pubTime":"2026-04-14 04:20","pubTimestamp":1776111643,"startTime":"0","endTime":"0","summary":"生物制药公司Revolution Medicines, Inc.在收盘后交易时段股价下挫1.6%，同时宣布将启动普通股与可转换优先票据的发行计划。此次融资举措旨在为公司的研发管线提供资金支持，特别是针对其创新肿瘤靶向疗法的临床开发。市场分析师指出，此类融资行为通常会对短期股价形成压力，但长期来看有助于推动企业核心业务发展。公司尚未披露具体发行规模与定价条款，但表示将根据市场条件适时推进发行工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172909747","title":"Revolution Medicines Inc拟发行7.5亿美元普通股及2.5亿美元2033年到期可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1172909747","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172909747?lang=zh_cn&edition=full","pubTime":"2026-04-14 04:02","pubTimestamp":1776110535,"startTime":"0","endTime":"0","summary":"生物制药公司Revolution Medicines Inc宣布启动双重融资计划，拟通过公开发行募集总额10亿美元资金。该方案包括发行价值7.5亿美元的普通股，同时配售2.5亿美元于2033年到期的可转换优先票据。此次融资将用于推进其肿瘤靶向治疗管线的临床开发，并加强企业运营资本储备。\n可转换票据持有人有权在特定条件下将债务转换为公司普通股，这种融资结构既能为企业提供长期资金支持，又可能降低未来股权稀释风险。市场分析师指出，大规模融资动作显示公司正加速核心项目的商业化布局，尤其在RAS抑制剂领域的技术突破备受行业关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129912833","title":"抗癌新药晚期研究显成效，Revolution Medicines盘前股价飙升33.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129912833","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129912833?lang=zh_cn&edition=full","pubTime":"2026-04-13 20:08","pubTimestamp":1776082091,"startTime":"0","endTime":"0","summary":"在最新公布的临床试验数据中，Revolution Medicines公司研发的口服抗癌药物展现出显著疗效，成功延长晚期癌症患者的生存期。受此利好消息提振，该公司股价在盘前交易时段大幅攀升33.5%，创下近期单日最大涨幅。这项针对晚期实体瘤患者的III期研究显示，与现有标准疗法相比，使用Revolution Medicines实验性药物的患者群体在总生存期指标上取得统计学意义的改善。随着后续研发进程的推进，该疗法有望成为特定癌症亚型的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146944010","title":"Daraxonrasib在转移性胰腺癌关键3期Rasolute 302临床试验中展现前所未有的总生存期获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1146944010","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146944010?lang=zh_cn&edition=full","pubTime":"2026-04-13 20:06","pubTimestamp":1776081992,"startTime":"0","endTime":"0","summary":"在针对转移性胰腺癌患者开展的关键性Rasolute 302三期临床试验中，Daraxonrasib表现出前所未有的总生存期获益。这一突破性进展为晚期胰腺癌治疗领域带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153407437","title":"Revolution Medicines：Daraxonrasib在针对转移性胰腺癌患者的3期Rasolute 302试验中显示总体生存获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1153407437","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153407437?lang=zh_cn&edition=full","pubTime":"2026-04-13 20:03","pubTimestamp":1776081808,"startTime":"0","endTime":"0","summary":"Revolution Medicines公司宣布，其研发的Daraxonrasib在针对转移性胰腺癌患者开展的3期Rasolute 302试验中，展现出显著的总体生存获益。这一积极数据为晚期胰腺癌治疗领域带来了新的希望。\n该试验结果进一步验证了Daraxonrasib在改善患者生存期方面的潜力，有望为临床治疗提供新的有效选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110233180","title":"Revolution Medicines：Daraxonrasib在胰腺癌患者中总体耐受性良好，安全性可控且无新发风险信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1110233180","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110233180?lang=zh_cn&edition=full","pubTime":"2026-04-13 20:01","pubTimestamp":1776081677,"startTime":"0","endTime":"0","summary":"Revolution Medicines公司宣布，其研发的Daraxonrasib在胰腺癌（PDAC）患者中展现出良好的耐受性特征。临床数据显示，该药物的安全性整体可控，未出现新的安全性风险信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198800251","title":"Revolution Medicines启动Rasolute 303三期临床试验，评估Daraxonrasib作为转移性胰腺癌一线疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1198800251","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198800251?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:02","pubTimestamp":1775131343,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. (RVMD) 已正式启动Rasolute 303三期临床试验的患者给药工作，该项研究旨在评估其核心候选药物Daraxonrasib作为转移性胰腺癌患者一线治疗方案的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":-0.0122},{"period":"3month","weight":0.5166},{"period":"6month","weight":0.8738},{"period":"1year","weight":2.7122},{"period":"ytd","weight":0.8736}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.714286,"avgChangeRate":0.029081},{"month":7,"riseRate":0.5,"avgChangeRate":-0.000709},{"month":8,"riseRate":0.666667,"avgChangeRate":0.059948},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}